OyaGen
Private Company
Total funding raised: $5.3M
Overview
OyaGen is a privately held, preclinical-stage biotechnology company founded in 2003 with a dual focus on proprietary drug discovery and contract research services. Its core pipeline targets viral infections, including HIV, Ebola, and coronaviruses, with a platform aimed at disabling key viral proteins. The company operates from a state-of-the-art lab in the Rochester BioVenture Center and is seeking significant capital to advance its lead HIV candidate into clinical trials while exploring strategic partnerships or M&A.
Technology Platform
High-throughput and high-content screening (HTS/HCS) platform for drug discovery, specializing in cell-based and biochemical assay development to identify compounds that target specific viral proteins (e.g., HIV Vif, Ebola VP40) and disease mechanisms.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
OyaGen competes in highly competitive fields against large pharmaceutical companies and well-funded biotechs developing next-generation HIV therapies and antivirals. Its niche lies in its unique viral protein targets (Vif, VP40) and its dual role as a service provider, though it lacks the clinical-stage assets of many competitors.